The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 3, 1997, Pages 316-321

  Hill, Gary E ^b   Whitten, Charles W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

adhesion molecules; atherogenesis; inflammation; nitric oxide; vascular endothelium

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PROSTACYCLIN;

ATHEROGENESIS; CAPILLARY PERMEABILITY; CELL ADHESION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0030918721     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90101-4     Document Type: Review

References (76)

1. Davies MG, Hagen P: The vascular endothelium. Ann Surg 218:593-609, 1993
2. Wright SD, Ramos RA, Tobias PS, et al: CD14, a receptor for complexes of lipopolysaccharide (LPS) binding protein. Science 249: 1431-1433, 1990
3. Menasché P, Haydar S, Peynet J, et al: A potential mechanism of vasodilation after warm heart surgery. J Thorac Cardiovasc Surg 107:293-299, 1994
4. Schneider F, Lutun P, Boudjema K, et al: In vivo evidence of enhanced guanylyl cyclase activation during the hyperdynamic circulation of acute liver failure. Hepatology 19:38-44, 1994
5. Harward TRS, Martin TD, Welborn MB, et al: Tumor necrosis factor-α (TNF), interleukin-1β (IL-1β), and interleukin-8 (IL-8) are released following thoracoabdominal aneurysm repair and TNF-levels are related to patient outcome. Surg Forum 46:360-362, 1995
6. Springer TA: Adhesive receptors of the immune system. Nature 346:425-434, 1990
7. Kimmel SC, van de Stouwe MJ, Levin RI, et al: A final common pathway for anti-inflammatory agents: Inhibition of leukocyte-endothelial interactions. Trans Assoc Am Physicians 104:113-124, 1991
8. Pober JS: Cytokine-mediated activation of vascular endothelium. Am J Pathol 133:426-433, 1988
9. Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037-1050, 1990
10. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 65:859-873, 1991
11. Carlos TM, Harlan JM: Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 114:5-28, 1990
12. Wilson I, Gillinov AM, Curtis WE, et al: Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 82:II372-II379, 1993
13. Gillinov AM, Redmond JM, Zehr KJ, et al: Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg 57:126-133, 1994
14. Johnson D, Thompson D, Hurst T, et al: Neutrophil-mediated acute lung injury after extracorporeal circulation. J Thorac Cardiovasc Surg 107:1193-1202, 1994
15. Entman ML, Youker K, Shoji T, et al: Neutrophil-induced oxidative injury of cardiac myocytes. J Clin Invest 90:1335-1345, 1992
16. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989
17. Osborn L: Leukocyte adhesion to endothelium in inflammation. Cell 62:3-6, 1990
18. Kukielka GL, Smith CW, Manning AM, et al: Induction of interleukin-6 synthesis in the myocardium. Circulation 92:1866-1875, 1995
19. Weyrich AS, Ma X, Lefer DJ, et al: In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 91:2620-2629, 1993
20. Royston D: Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 27:s42-s49, 1996 (suppl 1)
21. Rinder CS, Mathew JP, Rinder HM, et al: Modulations of platelet surface adhesive receptors during cardiopulmonary bypass. Anesthesiology 75:563-570, 1991
22. Todoroki N, Watanabe Y, Akaike T, et al: Enhancement by IL-1 and IFN- of platelet activation: Adhesion to leukocytes via GMP-140/ PADGEM protein (CD62). Biochem Biophys Res Commun 179:756-761, 1991
23. Kubes P: Polymorphonuclear leukocyte-endothelium interaction: A role for pro-inflammatory and anti-inflammatory molecules. Can J Physiol Pharmacol 71:88-97, 1993
24. Camussi G, Tetta C, Bussolino F, et al: Synthesis and release of platelet-activating factor is inhibited by plasma α1-proteinase inhibitor or α1-antichymotrypsin and is stimulated by proteinases. J Exp Med 168:1293-1306, 1988
25. Tonneson MG: Neutrophil-endothelial cell interactions: Mechanisms of neutrophil adherence to vascular endothelium. J Invest Dermatol 93:535-585, 1989 (suppl 2)
26. Lehr HA, Guhlmann A, Nolte D, et al: Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J Clin Invest 87:2036-2041, 1991
27. Bussolino F, Camussi G, Aglietta M, et al: Human endothelial cells are targets for platelet activating factor. J Immunol 139:2439-2446, 1987
28. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
29. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 88:4651-4655, 1991
30. Fukuda H, Sawa Y, Kadoba K, et al: Supplement of nitric oxide attenuates neutrophil mediated reperfusion injury. Circulation 92:II413-II416, 1995 (suppl II)
31. Kubes P, Granger DN: Nitric oxide modulates microvascular permeability. Am J Physiol 262:H611-H615, 1992
32. Salvemini D, Masini E, Pistelli A, et al: Nitric oxide: A regulatory mediator of mast cell reactivity. J Cardiovasc Pharm 17:s258-s264, 1991 (suppl 3)
33. Ma X, Weyrich AS, Lefer DJ, Lefer AM: Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 72:403-412, 1993
34. Chollet-Martin S, Gatecel C, Kermarrec N, et al: Alveolar neutrophil functions and cytokine levels in patients with adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 153:985-990, 1996
35. Matheis G, Sherman MP, Buckberg GD, et al: Role of I-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 262:H616-H620, 1992
36. Walter R, Schaffner A, Schoedon G: Differential regulation of constitutive and inducible nitric oxide production by inflammatory stimuli in murine endothelial cells. Biochem Biophys Res Commun 202:450-455, 1994
37. Alican I, Kubes P: A critical role for nitric oxide in intestinal barrier function and dysfunction. Am J Physiol 270:G225-G237, 1996
38. Boughton-Smith NK, Evans SM, Laszlo F, et al: The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol 110:1189-1195, 1993
39. Thiemermann C, Wu CC, Piper J, et al: Aminoguanidine attenuates the delayed circulatory failure in endotoxin and haemmorrhagic shock in the anesthetized rat. Can J Physiol Pharmacol 72: P14.2.22, 1994
40. Cronstein BN, Kimmel SC, Levin RI, et al: A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89:9991-9995, 1992
41. Radomski MW, Palmer RMJ, Moncada S: Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 87:10043-10047, 1990
42. Hill GE, Alonso A, Spurzem JR, et al: Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-1662, 1995
43. Nishijima J, Hiraoka N, Murata A, et al: Protease inhibitors (gabexate, mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukoc Biol 52:262-268, 1992
44. Tumen J, Meyrick B, Berry L, et al: Antiproteases protect cultured lung endothelial cells from endotoxin injury. J Appl Physiol 65:835-843, 1988
45. Kilbourn RG, Belloni P: Endothelial cell production of nitrogen oxides in response to IFN in combination with TNF, IL-1, or endotoxin. J Natl Cancer Inst 82:772-776, 1990
46. Hill CE, Taylor JA, Robbins RA: Differing effects of aprotinin and epsilon amino caproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thor Surg 61:74-77, 1997
47. Cronstein BN, Levin RI, Belanoff J, et al: Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 78:760-770, 1986
48. Olafsson B, Forman MB, Puett DW, et al: Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no-reflow phenomenon. Circulation 76:1135-1145, 1987
49. Galinanes M, Bullough D, Mullane KM, et al: Sustained protection by acadesine against ischemia- and reperfusion-induced injury. Circulation 86:589-597, 1992
50. Leung JM, Stanley T, Mathew J, et al: An initial, multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. Anesth Analg 78:420-434, 1994
51. Triplett DA: Biochemistry of blood coagulation, in Triplett DA (ed): Hemostatis - A Case-Oriented Approach. New York, NY, Igaku-Shoin, 1985, pp 1-27
52. Faint RW: Platelet-neutrophil interactions: Their significance. Blood Rev 6:83-91, 1992
53. Collen D: On the regulation and control of fibrinolysis. Thromb Haemost 43:77-88, 1980
54. Rijken DC, Wijngaards G, Collen D: Tissue-type plasminogen activator from human tissue and cell cultures and its occurrence in plasma, in Collen D, Lijnen HR, Verstraete M: Thrombolysis: Biologic and Therapeutic Properties of New Thrombolytic Agents. Edinburgh, Churchill Livingstone, 1985
55. Collen D, Lijnen HR: The fibrinolytic system in man: An overview, in Collen D, Lijnen HR, Verstraete M: Thrombolysis: Biologic and Therapeutic Properties of New Thrombolytic Agents. Edinburgh, UK, Churchill Livingstone, 1985, pp 1-14
56. Griffin JH: Clinical studies of protein C. Semin Thromb Hemost 10:162-166, 1984
57. Key NS: Scratching the surface: Endothelium as a regulator of thrombosis, fibrinolysis, and inflammation. J Lab Clin Med 120:184-186, 1992
58. Dittman WA, Majerus PW: Structure and function of thrombomodulin: A natural anticoagulant. Blood 75:329-334, 1990
59. Esmon CT, Taylor FB, Snow TR: Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 66:160-165, 1991
60. Dahlback B: Protein S and C4b binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 66:49-61, 1991
61. Esmon CT: Inflammation and thrombosis: The impact of inflammation on the protein C anticoagulation pathway. Haematologica 80:49-56, 1995 (suppl 2)
62. Ruggeri ZM: Von Willebrand's disease and the mechanisms of platelet function. Ciba Found Symp 189:35-45, 1995
63. Wagner DD, Bonfanti R: Von Willebrand factor and the endothelium. Mayo Clin Proc 66:621-627, 1991
64. Vassalli JD, Sapino AP, Belin D: The plasminogen activator/ plasmin system. J Clin Invest 88:1067-1122, 1991
65. Schleef RR, Bevilacqua MP, Sawdey M, et al: Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797-5803, 1988
66. Gerritsen ME: Eicosanoid production by the coronary microvascular endothelium. Fed Proc 47:47-53, 1987
67. Radomski MW, Moncada S: The biologic and pharmacologic role of nitric oxide in platelet function. Adv Exp Med Biol 344:251-264, 1993
68. Hladovec J, Rossmann P: Circulating endothelial cells isolated together with platelets and experimental modification of their counts in rats. Thromb Res 3:665-674, 1973
69. Wiemar B, Delvos U: The mechanism of fibrin-induced disorganization of cultured human endothelial cell monolayers. Arteriosclerosis 6:139-145, 1986
70. Lo SK, Del Vecchio PJ, Lum H, et al: Fibrin contact increases endothelial permeability to albumin. J Cell Physiol 151:63-70, 1992
71. Ross R: The pathogenesis of atherosclerosis: An update. N Engl J Med 314:488-500, 1986
72. Kadish JL: Fibrin and atherogenesis: A hypothesis. Atherosclerosis 33:409-413, 1979
73. Bordia A, Verma SK, Vyas A, et al: Effect of essential oil of onion and garlic on experimental atherosclerosis in rabbits. Atherosclerosis 26:379-386, 1977
74. Munkvad S, Gram J, Jesperson J: A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 11:525-528, 1990
75. Albelda SM: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68:4-17, 1993
76. Wendel HP, Heller W, Michel J, et al: Lower cardiac tropinin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 109:1164-1172, 1995